Equity Research, Broker Reports, and media content on Verona Pharma

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Verona Pharma
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Verona Pharma

Company Profile

  • Personnel
  • Sven Jan-Anders Karlsson, CEO
  • Piers Morgan, CFO

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Verona Pharma. We currently have 113 research reports from 6 professional analysts.

  • Open: N/A
  • Range Today: N/A
  • 52 Week: 31.5/75.0p
  • Daily Volume: N/A
  • Daily Liquidity: (0%)
  • # Shares: 106.5m
  • Market Cap: £49.5m
  • Latest PE (hist):
  • Div Yield:
Date Source Announcement
06Jul20 16:04 GNW Verona Pharma plc: Issue of Equity and Total Voting Rights
14May20 07:00 GNW Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
12May20 13:11 GNW Director/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings
01May20 17:12 GNW Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference
30Apr20 07:00 GNW Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020
23Apr20 07:00 GNW Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update
16Apr20 12:12 GNW Verona Pharma plc: Results of AGM
  • Frequency of research reports


  • Research reports on

    Verona Pharma

  • Providers covering

    Verona Pharma